pembrolizumab
merck
['keynote-224', 'pembro', 'hcc', '4109']
3-year follow-up of the phase 2 keynote-224 pembrolizumab in 1st line hcc --&gt; "long-term" survival in hcc?!
j clin oncol 40, 2022 (suppl 16; abstr 4109)
#livercancer #hcc #immunotherapy 
Physician-scientist, focussed on translational research in hepatobiliary cancer and precision medicine